|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05.
|
31759989 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed that PGC-1α and NT-PGC-1α were decreased in MI-induced heart failure mice.
|
31133853 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We generated a cardiac specific PGC-1α knockout mice (KO) to specifically induce metabolic dysregulation typically accompanied by HF and performed a non-targeted LC-MS metabolite profiling analysis of heart, plasma, liver, and skeletal muscle to identify metabolites associated with cardiac specific metabolic remodelling.
|
29931052 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
PGC-1α-cKO (cardiac-specific PGC-1α knockout) mice showed phenotypic similarity to the pressure-overload-induced heart failure model in wild-type mice, such as contractile dysfunction and downregulation of PGC-1α target genes, even under basal conditions.
|
30798619 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed that PGC-1α and NT-PGC-1α were decreased in MI-induced heart failure mice.
|
31133853 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
PGC-1α-cKO (cardiac-specific PGC-1α knockout) mice showed phenotypic similarity to the pressure-overload-induced heart failure model in wild-type mice, such as contractile dysfunction and downregulation of PGC-1α target genes, even under basal conditions.
|
30798619 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum Peroxisome Proliferator-activated Receptor Gamma Coactivator-1α Related to Myocardial Energy Expenditure in Patients With Chronic Heart Failure.
|
30638602 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We generated a cardiac specific PGC-1α knockout mice (KO) to specifically induce metabolic dysregulation typically accompanied by HF and performed a non-targeted LC-MS metabolite profiling analysis of heart, plasma, liver, and skeletal muscle to identify metabolites associated with cardiac specific metabolic remodelling.
|
29931052 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HG-HF significantly depressed expression of PGC-1α (peroxisome proliferator-activated receptor-γ coactivator-1α) and OPA1 (optic atrophy 1) by reducing [Ca<sup>2+</sup>]<sub>i</sub>, whereas OPA1 supplementation partly reversed those detrimental effects induced by TRPV1<sup>-/-</sup> Furthermore, capsaicin treatment not only attenuated CMECs injury induced by HG-HF but also mitigated cardiac microvascular injury induced by T2DM.
|
29735636 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
Biomarker
|
disease |
BEFREE |
An interaction between ERRα and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) has also recently been shown to regulate an enzyme in the β-oxidation of free fatty acids, thereby suggesting that ERRα plays an important role in obesity and type 2 diabetes.
|
29216352 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The impact of six polymorphisms of PGC-1α with Type 2 Diabetes (T2D) susceptibility was evaluated on 1125 samples comprising of 554 T2D cases and 571 controls among three endogamous groups (Bania, Brahmin and Jat Sikh) of North-West India (Punjab).
|
29063962 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide variant of the PPARGC1A gene (rs8192678) is associated with T2D susceptibility, relative risk of obesity and insulin resistance, and lower indices of β cell function.
|
29186342 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, the present study demonstrated that NT‑PGC‑1α alleviated PE‑induced mitochondrial impairment and decreased lipid droplet accumulation in NRCMs, indicating that NT‑PGC‑1α may have ameliorated mitochondrial energy defects in NRCMs, and may be considered as a potential target for the treatment of heart failure.
|
29901150 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, the present study demonstrated that NT‑PGC‑1α alleviated PE‑induced mitochondrial impairment and decreased lipid droplet accumulation in NRCMs, indicating that NT‑PGC‑1α may have ameliorated mitochondrial energy defects in NRCMs, and may be considered as a potential target for the treatment of heart failure.
|
29901150 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
Biomarker
|
disease |
BEFREE |
We hypothesized that targeting PGC-1α acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D.
|
28340340 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Melatonin supplementation in combination with exercise behavior may ameliorate IR, hypertension and exercise performance or fatigue possibly by improving antioxidative activities, hyperlipidemia, inflammatory cytokines via up-regulation of GLUT4, PGC-1 α and mitochondrial biogenesis in T2DM rats.
|
28578257 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the anti-diabetic effect of PPD and PPT appeared to be partially mediated by the suppression of hepatic metabolism genes expression such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase, as well as facilitating lipid metabolism genes expression such as microsomal TG transfer protein in the liver tissues of T2DM mice.
|
28824430 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
Biomarker
|
disease |
BEFREE |
Histological results confirmed that renal expression of key proteins was reduced in DKD patients with respect to mitochondrial biogenesis (PGC-1α, p-AMPK) and FA oxidation (PPAR-α, CPT-1) as compared to that in the control and T2DM groups.
|
28956034 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thermogenic genes expressions in epicardial adipose tissue (UCP1: OR 0.617, 95%CI 0.103-0.989, p=0.042; PGC1α: OR 0.416, 95%CI 0.171-0.912, p=0.031; PRDM16: OR 0.643, 95%CI 0.116-0.997, p=0.044) were showed as protective factors against the presence of heart failure with reduced left ventricular ejection fraction, and age (OR 1.643, 95%CI 1.001-3.143, p=0.026), presence of coronary artery disease (OR 6.743, 95%CI 1.932-15.301, p<0.001) and type-2-diabetes mellitus (OR 4.031, 95%CI 1.099-7.231, p<0.001) were associated as risk factors.
|
28824327 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
Biomarker
|
disease |
BEFREE |
The energy homeostasis is regulated by a network consisting of "fuel gauze" called AMP-activated protein kinase (AMPK), the NAD<sup>+</sup> dependent type III deacetylase (SIRT1) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) which is disrupted in T2D.
|
28751004 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Haplotype comparison analysis indicated that CTTCGGG and CTCTGGG haplotypes with the order of PPARG rs1801282 C>G, PPARG rs3856806 C>T, PPARGC1A rs8192678 C>T, PPARGC1A rs2970847 C>T, PPARGC1A rs3736265 G>A, PPARGC1B rs7732671 G>C and PPARGC1B rs17572019 G>A polymorphisms in gene position significantly increased the risk of T2DM.
|
28418876 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
Biomarker
|
disease |
BEFREE |
A haplotype-based gene-gene interaction was observed significantly (U = -6.28, P < .001), indicating the possibility of an interaction between haplotype AAG of the PPARGC1A gene and haplotypes CTCG (odds ratio [OR] = 1.745, 95% confidence interval [95% CI] 1.069-2.847) and CTCA (OR = 0.239, 95% CI 0.060-0.958) of the UCP1 gene.Haplotype-based interaction between the PPARGC1A and UCP1 genes is associated with IFG or T2DM among residents in Henan, China.
|
28591028 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Associations of PGC-1α variants rs10517030 and rs10212638 with T2DM were analyzed in a dominant genetic model, and were tested for interactions of genotypes and nutrients with T2DM risk.
|
28488691 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
PGC-1α, a key regulator of energy metabolism, seems to be a relevant therapeutic target to rectify the energy deficit observed in heart failure (HF).
|
27876471 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thermogenic genes expressions in epicardial adipose tissue (UCP1: OR 0.617, 95%CI 0.103-0.989, p=0.042; PGC1α: OR 0.416, 95%CI 0.171-0.912, p=0.031; PRDM16: OR 0.643, 95%CI 0.116-0.997, p=0.044) were showed as protective factors against the presence of heart failure with reduced left ventricular ejection fraction, and age (OR 1.643, 95%CI 1.001-3.143, p=0.026), presence of coronary artery disease (OR 6.743, 95%CI 1.932-15.301, p<0.001) and type-2-diabetes mellitus (OR 4.031, 95%CI 1.099-7.231, p<0.001) were associated as risk factors.
|
28824327 |
2017 |